Identification of A2BAR as a potential target in colorectal cancer using novel fluorescent GPCR ligands
| dc.contributor.affiliation | Universidade de Santiago de Compostela. Centro de Investigación en Medicina Molecular e Enfermidades Crónicas (CiMUS) | |
| dc.contributor.affiliation | Universidade de Santiago de Compostela. Centro de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS) | |
| dc.contributor.affiliation | Universidade de Santiago de Compostela. Departamento de Farmacoloxía, Farmacia e Tecnoloxía Farmacéutica | |
| dc.contributor.affiliation | Universidade de Santiago de Compostela. Departamento de Química Inorgánica | |
| dc.contributor.author | Barbazán García, Jorge | |
| dc.contributor.author | Majellaro, Maria | |
| dc.contributor.author | Martínez Rodríguez, Antón Leandro | |
| dc.contributor.author | Brea Floriani, José Manuel | |
| dc.contributor.author | Sotelo Pérez, Eddy | |
| dc.contributor.author | Abal Posada, Miguel | |
| dc.date.accessioned | 2026-01-13T12:47:02Z | |
| dc.date.available | 2026-01-13T12:47:02Z | |
| dc.date.issued | 2022-07-18 | |
| dc.description.abstract | G-protein coupled receptors (GPCRs) have been largely targeted in a wide range of diseases, but few therapies have been directed against GPCRs in the field of cancer, partly because of the lack of effective target identification strategies. Here, using colorectal cancer (CRC) as a model, we explored the gene expression of a panel of GPCRs in tumor and stromal cells, identifying specific gene sets defining each cellular compartment. We selected the adenosine receptor 2B (A2BAR), specifically expressed in cancer cell lines compared with stromal cells, to explore the use of fluorescent ligands that can be used for target visualization. Fluorescent probes allowed semi-quantitative receptor mapping in living cells and validated the specific expression of A2BAR in CRC cell lines. As well, fluorescent ligands were effective at monitoring real-time A2BAR receptor labeling using live-imaging modalities, and displayed high efficiency when used to label complex 3D cellular systems such as tumor spheroids. Finally, we validated A2BAR as a potential pharmacological tool in CRC, using selective antagonists, finding a reduction in tumor cell proliferation. This proof-of-concept study suggests the use of fluorescent ligands for GPCR characterization through imaging, and as possible new tools used for target validation in drug screening methodologies | |
| dc.description.peerreviewed | SI | |
| dc.description.sponsorship | This work was supported by the Juan de la Cierva grant program to Jorge Barbazán (IJC2018-036875-I) and CIBERONC (CB16/12/00328). We also thank the Consellería de Cultura, Educación e Ordenación Universitaria of the Galician Government (grant: ED431B 2020/43), Centro Singular de Investigación de Galicia accreditation 2019–2022 (ED431G 2019/03) and the European Regional Development Fund (ERDF), Ministerio de Ciencia e Innovación-Agencia Estatal de Investiogación-FEDER-EU (PID2021-124010OB-100) for the financial support | |
| dc.identifier.citation | Jorge Barbazán, Maria Majellaro, Antón L. Martínez, José M. Brea, Eddy Sotelo, Miguel Abal, Identification of A2BAR as a potential target in colorectal cancer using novel fluorescent GPCR ligands, Biomedicine & Pharmacotherapy, Volume 153, 2022, 113408, ISSN 0753-3322, https://doi.org/10.1016/j.biopha.2022.113408 | |
| dc.identifier.doi | 10.1016/j.biopha.2022.113408 | |
| dc.identifier.essn | 1950-6007 | |
| dc.identifier.uri | https://hdl.handle.net/10347/45091 | |
| dc.journal.title | Biomedicine & Pharmacotherapy | |
| dc.language.iso | eng | |
| dc.publisher | Elsevier | |
| dc.relation.projectID | info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023/PID2021-124010OB-I00/ES/FARMACOS MULTI-DIANA EN LA INMUNOTERAPIA DEL CANCER: DESCUBRIMIENTO DE LIGANDOS QUE ACTUAN SINERGICAMENTE EN DOS PUNTOS DE CONTROL INMUNITARIOS EN EL MICROAMBIENTE TUMORAL | |
| dc.relation.publisherversion | https://doi.org/10.1016/j.biopha.2022.113408 | |
| dc.rights | © 2022 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-ND license | |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | en |
| dc.rights.accessRights | open access | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.subject | Colorectal cancer | |
| dc.subject | GPCRs | |
| dc.subject | Adenosine receptors | |
| dc.subject | Tumor microenvironment | |
| dc.subject | Fluorescent ligands | |
| dc.subject | Drug screening | |
| dc.title | Identification of A2BAR as a potential target in colorectal cancer using novel fluorescent GPCR ligands | |
| dc.type | journal article | |
| dc.type.hasVersion | VoR | |
| dc.volume.number | 153 | |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | efe7f464-2f77-4a92-915f-fda4128451fa | |
| relation.isAuthorOfPublication | 67b19be7-64a8-45c8-a6e4-ed48a4410ef8 | |
| relation.isAuthorOfPublication | d655a7d4-67dc-48b3-994f-1e53e75ec186 | |
| relation.isAuthorOfPublication.latestForDiscovery | efe7f464-2f77-4a92-915f-fda4128451fa |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- 2022_BiomPharm_Barbazan_Identification.pdf
- Size:
- 12.11 MB
- Format:
- Adobe Portable Document Format